Fresenius Medical Care (ETR:FME) Stock Upgrade
Fresenius Medical Care (ETR:FME) was just upgraded by Joh. Berenberg Gossler & Co. KG to a respectable Buy rating in a comprehensive report revealed to clients on Saturday morning. The firm currently has a EUR 92.00 price target on the shares. This target is 21.47% from FME’s current share price.
From a total of 15 analysts covering Fresenius Medical Care (ETR:FME) stock, 8 rate it a ”Buy”, 0 a “Sell”, and 7 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is €93 while the lowest target price is €68.70. The mean of all analyst targets is €82.19 with a 8.50% above today’s (€75.75) stock price. Fresenius Medical Care was the topic of 32 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs upgraded shares on November 25 to “Buy” rating. Credit Suisse upgraded shares to “Outperform” rating and €88 target share price in a report from a November 12. Berenberg upgraded FME stock in a recent report from November 21 to “Buy” rating. Warburg Research maintained the rating on November 5. Warburg Research has a “Hold” rating and a €85 price target on shares. Finally, Bernstein upgraded the stock to “Outperform” rating in a report issued on a November 17.
The stock decreased 0.12% or EUR 0.09 on December 4, striking EUR 75.75. Approximately 718,559 shares of stock traded hands or 4.76% up from the average. Fresenius Medical Care AG & Co. KGaA (ETR:FME) has risen 6.00% since November 5, 2015 and is uptrending. It has outperformed by 8.78% the S&P500.
Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. It has 26.08 P/E ratio. The Firm provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services.